Why is Ellume hitting headlines today?

Brisbane-based diagnostics developer Ellume is back in the headlines.

Rapid Antigen Test taking place.

Image source: Getty iMAGES

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Ellume is in the spotlight as the United States Government looks to buy another 500 million RATs
  • Additionally, the company has reportedly started working to get approval to sell its tests in Australia
  • There's still no word of Ellume listing on the ASX

Brisbane-based diagnostics developer Ellume is back in the headlines as demand for rapid antigen tests (RATs) continues to hit Australia and the world.

However – while there has been speculation – there's been no word as to whether we'll see shares in the company on our home-spun market.

Ellume isn't listed on the ASX. In fact, there's still nowhere for investors to publicly buy shares in the company.

Let's take a closer look at what's got many excited about the company this morning.

What's got ASX-watchers excited about Ellume on Friday?

The first news that might have put the spotlight on Ellume this morning came from its major market, the United States.

While most Australians slept last night, President Joe Biden announced that the United States Government will be handing out 1 billion free tests to citizens – 500 million more than previously promised. That means the government will be off to the shops looking to snap up the extra RATs.

Ellume's test was the first over the counter at-home RAT to be approved by the country's Food and Drug Administration back in December 2020. Since then, the United States Government has snapped up millions of them.

That likely leaves many wondering if its products could once again be in the government's cart.  

Back home, the ABC today reported it understands that Ellume has begun the journey of receiving Therapeutic Goods Administration (TGA) approval for its RAT tests.

If given the green light by the regulator, the tests will be allowed to be purchased by Australian consumers. Though, that doesn't mean they'll be on shelves any time soon.

Previously, Brisbane Times reported, while Ellume planned to submit its product for TGA approval early this year, the company stated it can't supply Australia with RATs until mid-2022.

However, the scramble for RATs that has likely put focus on Ellume also seems to have boosted the share price of its ASX-listed peers.

Right now, the AnteoTech Ltd (ASX: ADO) share price is up 3.92%. Meanwhile, that of Lumos Diagnostic Holdings Ltd (ASX: LDX) has gained 2.5%. Both companies are selling their RATs overseas while they await TGA clearance.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Broker gives its verdict on BHP shares

Let's see what Bell Potter is saying about the Big Australian.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Woman holding gold bar and cheering.
Gold

Why Macquarie expects this surging ASX 200 gold stock could leap another 40%

Macquarie forecasts another year of strong outperformance from this fast-rising ASX 200 gold miner.

Read more »

A young woman looks at here phone as she strides out in an airport dragging her wheelie bag behind her and smiling widely.
Broker Notes

Macquarie tips 15% upside for this ASX 200 industrials stock

Is this transportation business preparing for take-off?

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »